TGFBR1*6A and cancer risk: A meta-analysis of seven case-control studies Journal Article
| Authors: | Kaklamani, V. G.; Hou, N.; Bian, Y.; Reich, J.; Offit, K.; Michel, L. S. ; Rubinstein, W. S.; Rademaker, A.; Pasche, B. |
| Article Title: | TGFBR1*6A and cancer risk: A meta-analysis of seven case-control studies |
| Abstract: | Purpose: TGFBR1*6A is a hypomorphic polymorphic allele of the type I transforming growth factor beta receptor (TGFBR1). TGFBR1*6A is a candidate tumor susceptibility allele that has been associated with an increased incidence of various types of cancer. This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer. Patients and Methods: All published case-control studies assessing the germline frequency of TGFBR1*6A were included. Studies assessing TGFBR1*6A in tumors were excluded. The results of seven studies comprising 2,438 cases and 1,846 controls were pooled and analyzed. Results: Overall, TGFBR1*6A carriers have a 26% increased risk of cancer (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.07 to 1.49). Cancer risk for TGFBR1*6A homozygotes (OR, 2.53; 95% CI, 1.39 to 4.61) is twice that of TGFBR1*6A heterozygotes (OR, 1.26; 95% CI, 1.04 to 1.51). Analysis of various types of tumors shows that TGFBR1*6A carriers are at increased risk of developing breast cancer (OR, 1.48; 95% CI, 1.11 to 1.96), hematological malignancies (OR, 1.70; 95% CI, 1.13 to 2.54), and ovarian cancer (OR, 1.53; 95% CI, 1.07 to 2.17). Carriers of TGFBR1*6A. who are from the United States are at increased risk of colorectal cancer (OR, 1.38; 95% CI, 1.02 to 1.86). However, Southern European TGFBR1*6A. carriers have no increased colorectal cancer risk. There is no association between TGFBR1*6A and bladder cancer. Conclusion: TGFBR1*6A is emerging as a high-frequency, low-penetrance tumor susceptibility allele that predisposes to the development of breast, ovarian, and colorectal cancer, as well as hematologic malignancies. © 2003 by American Society of Clinical Oncology. |
| Keywords: | adolescent; adult; aged; middle aged; case control study; genetics; case-control studies; clinical trial; cancer risk; neoplasm; neoplasms; colorectal cancer; metabolism; allele; cancer susceptibility; genetic predisposition to disease; ovary cancer; breast cancer; transforming growth factor beta; genetic association; genotype; alleles; odds ratio; heterozygote; bladder cancer; risk; hematologic malignancy; systematic review; homozygote; transforming growth factor beta receptor; receptors, transforming growth factor beta; genetic predisposition; race difference; polymorphism, genetic; meta analysis; genetic polymorphism; transforming growth factor beta receptor 1; humans; human; male; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | 17 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2003-09-01 |
| Start Page: | 3236 |
| End Page: | 3243 |
| Language: | English |
| DOI: | 10.1200/jco.2003.11.524 |
| PUBMED: | 12947057 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work